<DOC>
	<DOCNO>NCT01564914</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy TRC105 patient recurrent progressive glioblastoma prior antiangiogenic therapy ( include anti-VEGF therapy )</brief_summary>
	<brief_title>A Phase 2 Evaluation TRC105 In Combination With Bevacizumab Treatment Of Recurrent Progressive Glioblastoma That Has Progressed Bevacizumab</brief_title>
	<detailed_description>Angiogenesis play central role progression solid cancer . TRC105 antibody CD105 , important non-VEGF angiogenic target proliferate endothelial cell . TRC105 inhibit angiogenesis , tumor growth metastases preclinical model . TRC105 well tolerate patient glioblastoma ( GBM ) single agent . The combination TRC105 combination bevacizumab demonstrate activity bevacizumab refractory cancer patient . We hypothesize TRC105 administer bevacizumab activity GBM patient progress bevacizumab . By target non-VEGF pathway , TRC105 potential complement VEGF inhibition bevacizumab , could represent major advance GBM therapy .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients histologically confirm glioblastoma , recurrent prior externalbeam fractionate radiotherapy temozolomide chemotherapy . 2 . Patients document radiographic progression follow bevacizumab therapy treatment glioblastoma . 3 . Patients 3 prior recurrence allow . 4 . Karnofsky performance status ≥ 70 % . 5 . Age ≥ 18 year old . 6 . Normal organ function Patients previous treatment TRC105 . Patients undergone major surgery ( e.g . intrathoracic , intraabdominal intrapelvic ) , open biopsy significant traumatic injury ≤ 4 week prior start study drug , patient minor procedure , percutaneous biopsy placement vascular access device ≤ 1 week prior start study drug , recover side effect procedure injury Patients cirrhosis , active viral nonviral hepatitis . Patients active bleed pathologic condition carry high risk bleeding , ( i.e . hereditary hemorrhagic telangiectasia ) . Patients currently receive anticoagulation treatment Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>